TABLE 1.
EBERs enhance tumorigenic potential of EBV-negative Akata BL cells
| Cell line | Level of EBER expressiona | No. of mice that developed tumors/no. tested | Time to tumor development (wk) |
|---|---|---|---|
| 3F2 (EBV−) | − | 0/4 | NAb |
| A.15 (EBV+) | +++ | 4/4 | 4.5 |
| 3F2 E3 | ++ | 5/9c | 10–15 |
| 3F2 E4 | ++ | 9/12 | 12–18 |
| 3F2 E10 | ++ | 8/9d | 13–18 |
| 3F2 BSA vector 1 | − | 0/7 | NA |
| 3F2 BSA vector 2 | − | 0/4 | NA |
| 3F2 BSK E | + | 6/8 | 14–19 |
| 3F2 BSK vector | − | 1/5 | 19 |
| A.2 E6 | +++ | 1/4 | 12 |
| A.2 E8 | +++ | 1/4 | 10 |
| A.2 E12 | +++ | 3/3 | 7–10 |
| A.2 BSA vector 1 | − | 0/4 | NA |
| A.2 BSA vector 2 | − | 0/4 | NA |
a
+++, wild-type or greater level of EBER expression; ++, 40 to 55% wild-type expression; +, <10% wild-type expression.
b
NA, not applicable.
c
Two additional mice were injected, but died tumor free at 5 and 16 weeks postinjection of unknown causes.
d
Two additional mice were injected, but died tumor-free at 7 and 11 weeks postinjection of unknown causes.